GPCR Stock Predictions
| Recent GPCR Stock Price | GPCR Stock Predictions | |
| $39.74 |  +102.57% |
$80.50 |
| Recent GPCR Analyst Ratings Breakdown, Making GPCR Stock Predictions | ||||
|---|---|---|---|---|
| Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
| Strong buy ratings: | 8 | 7 | 7 | 6 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 0 | 0 | 0 | 0 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.0 | 1.0 | 1.0 | 1.0 |
For the GPCR stock predictions from the analysts covering Structure Therapeutics Inc, we have collected all of the individual GPCR stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 8 different analysts covering GPCR (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since GPCR stock predictions may vary widely, another useful metric to consider is the median GPCR stock prediction, which represents the price at which half of the analysts
made GPCR stock predictions that were higher and half made GPCR stock predictions that were lower. This makes for a different take on the GPCR stock predictions out there, as compared to average or mean.
And that median across all the individual GPCR stock predictions was: $83.0 as of 2024-05-07.
The very highest of the GPCR stock predictions for one year price target was $93.0, while the very lowest of the GPCR stock predictions in the analyst group was
$58.0 (with a standard deviation of $12.873). Get the latest Zacks research report on GPCR — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
• MMC Stock Predictions
• GNK Stock Predictions
• SWCH Stock Predictions
• AMRX Stock Predictions
• BANC Stock Predictions
• FCCY Stock Predictions
• CYTK Stock Predictions
• MXIM Stock Predictions
• ESNT Stock Predictions
|
|||||||||
|
|
|
|
|
|
Free Email Alerts:
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
|
